PTAB deals Bass another blow
21-10-2015
Bass set for first IPR trial as Shire petition proceeds
09-10-2015
27-10-2015
St22 / Shutterstock.com
Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board (PTAB) for the second time in a month after it agreed to institute an inter partes review (IPR) of a patent covering a drug owned by NPS Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; Coalition for Affordable Drugs; IPR; PTAB; USPTO; patents; Gattex; NPS Pharmaceuticals